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The last few years have seen the development of several molecular designs to search for
mutations encoding resistance to antituberculous drugs in Mycobacterium tuberculosis.
Most of these are highly efficient for RIF-r detection and are well adapted to search for the
most relevant INH-R mutations. In this review, these new molecular approaches are
explained and are presented according to the molecular strategies on which they are
based. In this sense, techniques based on DNA-sequencing, electrophoresis and hybri-
dization are reviewed and the newer designs based on real-time PCR and microarrays are
also included. Molecular methods are sure to transform standard approaches to the issue
of resistance in the mycobacteriology laboratory. This will allow laboratories to speed up
the performance of resistance assays and provide access to essential information for
highly refined detection, follow-up and management of antibiotic resistance in M.
tuberculosis.
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I N T R O D U C T I O N
It is estimated that 3.2% of all new cases of tuber-
culosis worldwide are caused by multidrug-resis-
tant (MDR) strains [1] and, in some regions, the
incidence for MDR-tuberculosis (TB) is alarming
(14% in Estonia, 11% in Henan Province, China).
Apart from the obvious clinical, therapeutical and
epidemiological importance of these figures, MDR–
TB also has an economic impact, as the treatment
for this 3.2% is more expensive than the estimated
cost for all the remaining cases.
Knowledge of the susceptibility pattern of the
Mycobacterium tuberculosis (MTB) strain involved
in each case is essential to avoid inefficient therapy
and to optimise the antimicrobial efficacy of the
combined-drug regimen from the very beginning.
It enables us to increase the possibility of cure and
to curb the potential spread of high-risk strains in
the community. Therefore, physicians request sus-
ceptibility patterns as early as possible, and the
Centres for Disease Control recommends report-
ing resistance patterns within 28 days of receiving
the specimen in the laboratory [2]. In the last few
years, liquid-culture strategies have made it pos-
sible to accelerate the culture of mycobacteria and
the availibility of an antibiogram. Nevertheless, as
phenotypic susceptibility assays require strains
that have been subcultured in the presence of a
set of antituberculous agents, the possibilities for
accelerating the antibiogram are severely limited.
To obtain more rapid results, recourse must be
made to genotypic assays [3,4]. These involve
performing the analysis directly on the DNA with
the result that only the nucleic acid needs to be
extracted without having to subculture the strain.
The time necessary to determine the susceptibility
pattern is therefore reduced and the possibility
remains (still restricted to certain techniques) of
obtaining the antibiogram directly from the bacilli
in the clinical sample.
Recently, some molecular assays have been tai-
lored to obtain susceptibility patterns in MTB
thanks to a better understanding of the genetic
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Corresponding author and reprint requests: D. Garcı´a de
Viedma, Servicio de Microbiologı´a clı´nica y enfermedades
infecciosas, Hospital general universitario Gregorio Mara-
n˜o´n, C/Dr Esquerdo 46, 28007 Madrid, Spain
E-mail: dgviedma@microb.net
basis of resistance to antituberculous agents. Mole-
cular methods for detecting resistance are based
on assigning the presence/absence of certain
mutations in specific positions/genetic regions
which are known to confer resistance. The detec-
tion of resistance to anti-TB drugs by molecular
approaches is determined by the degree of under-
standing of the genetic basis of the resistance for
each of the drugs [5–7]. This varies somewhat
according to the different antibiotics used in the
combined anti-TB regimen, with more information
available for Rifampin (RIF) and Isonazid (INH),
the two drugs most efficacious against MTB.
G E N E T I C B A S I S O F R E S I S T A N C E
I N M T B
Most RIF-resistant strains have a mutation in an
81-bp region (named core rpoB, or RIF-resistance-
determining region RRDR) which is part of the
rpoB gene encoding the beta subunit of the DNA-
dependent RNA polymerase. Because synon-
ymous changes are very uncommon in this region,
the detection of any nucleotidic substitution
within this genetic region is a marker for resis-
tance. Some codons in this rpoB core region are
more frequently associated with resistance-encod-
ing mutations, especially 531, 526 and 516, and
some of them have been reported to be associated
with high-levels of resistance [8,9] or with resis-
tance against other rifamycins [10].
For INH the situation is more complex. Resis-
tance-mutations have been reported to map in at
least four different genetic loci: katG, encoding
catalase-peroxidase; inhA involved in fatty acid
elongation; ahpC encoding alkyl hydroperoxide
reductase, and oxyR involved in the regulation
of oxidative stress. Despite this complexity, one
codon, katG315, is most frequently associated with
resistance to INH (often at high levels), and there-
fore, the detection of resistance in many cases is
simplified. Additionally, resistant strains with
mutations in codon 315 have been reported to
be efficiently transmitted and to conserve intact
their virulence [11,12].
In the case of ethambutol, resistance mutations
have been found in the embCAB operon which
codes for different arabinosyl transferases that
have a role in lipoarabinomannan and arabinoga-
lactan synthesis. Resistance against the other first-
line anti-TB drug, streptomycin, is caused by
mutations in rrs, which codes for 16SRNA and
rpsL, which in turn codes for the ribosomal protein
12S.
Despite the fact that these are the genetic loci
most frequently found to encode resistance-muta-
tions in MTB, resistant strains with no mutations in
any of these regions have also been isolated.
Hence, the ubiquituous nature of resistance in
MTB and the need for additional efforts to com-
plete the genetic sequences involved in the devel-
opment of resistance.
M O L E C U L A R M E T H O D S F O R
D E T E C T I N G R E S I S T A N C E I N M T B
Molecular techniques search for resistance muta-
tions either directly or indirectly. The different
techniques that are applied for the genotypic ana-
lysis of resistance in MTB can be grouped into
three categories: electrophoresis, sequencing and
hybridization-based assays. The sequencing and
hybridization-based assays directly detect muta-
tions and can define the precise mutations involved,
whereas electrophoretic assays provide an indirect
method of detecting the existence of mutations
without having the ability to define the exact
nucleotidic substitution involved.
Electrophoresis-based techniques
The different electrophoresis-based approaches
search for mutations after analyzing the electro-
phoretic mobility of DNA fragments which include
the genetic regions involved in resistance. Mobility
shifts in these DNA fragments, when compared
with the mobility of wild type/reference sequences,
indicate the presence of mutations. In order to
facilitate the detection of mobility shifts, these meth-
ods analyse DNA structural variants (single-strand,
heteroduplexes) and select special electrophoretic
conditions (pH gradients, denaturing gels).
PCR–SSCP (single-strand-conformation-
polymorphisms)
This method is based on the conformational dis-
tortion that a nucleotide substitution can cause in a
single-strand DNA fragment. This conformational
change leads to an electrophoretic mobility differ-
ent to that of the wild-type single-strand fragment.
The procedure involves amplification by PCR of a
DNA fragment including the region of interest,
denaturation of this fragment, and running it in a
polyacrylamide gel together with the denatured
350 Clinical Microbiology and Infection, Volume 9 Number 5, May 2003
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 349–359
wild-type reference sample. Mobility shifts in the
clinical sample would indicate the presence of a
mutation in the region analyzed.
The advantages of this method are that it is
inexpensive, easy and quick. It does not require
complex devices and has a high specificity, and a
mobility shift is a good indicator of the existence of
a nucleotidic substitution. It has frequently been
used to search for resistance mutations against RIF
and INH [13–15], with higher sensitivity for RIF-r
than INH-r mutations. Trials to adapt this techni-
que to other drugs with more genetically complex
mechanisms of resistance such as PIR or EMB have
failed [16,17].
Some authors obtained positive results by using
SSCP directly with clinical samples, especially to
rule out the presence of mutations in susceptible
cases [15]. Not all nucleotidic changes are well
detected by SSCP, depending on the substitution
and the relative position of the affected codon
within the amplified fragment. In certain cases
interpretation is difficult and ambiguous and only
under extreme electrophoretic conditions do some
mutant strains lead to SSCPs [18]. Some of these
limitations could be eliminated by using long
performance gels, highly sensitive staining tech-
niques or fluorescent labeling of the products and
by processing them in an automatic sequencer [19],
thus increasing the sensitivity of the assay.
Heteroduplex analysis
Another method of detecting mutations based on
electrophoretic band-shifts is the detection of het-
eroduplexes in polyacrylamide gels. Again, the
technique depends on the PCR amplification of
the region of interest in the clinical isolate. This
amplicon from the clinical isolate is denatured and
then mixed with an equivalent amount of a dena-
tured amplicon from a reference wild-type strain
or, in other designs, from a universal heteroduplex
generator [20]. The mixture of amplicons is
allowed to cool slowly to reconstitute double-
strand DNA-renatured molecules. If the clinical
strain has no mutations in the region analyzed, the
homology between the single strands of the clin-
ical and reference amplicons would be complete,
with the result that the renatured duplexes would
be identical to the clinical/reference original DNA
homoduplexes. On the contrary, if a mutation
exists in the clinical amplicon, heteroduplexes
could be obtained by the renaturation of one
strand from the clinical mutant amplicon and
another from the reference strain. These hetero-
duplexes have an electrophoretic mobility differ-
ent than the original amplicons.
Some authors improve the sensitivity of the
detection of heteroduplexes by performing special
electrophoresis techniques such as DG-DGGE
(double-gradient denaturing gradient gel electro-
phoresis) which uses a double gradient (tempera-
ture and polyacrylamide) [21]. A modification of
the heteroduplex assay is the RNA/RNA mis-
match assay, in which the detection of heterodu-
plexes is performed on RNA hybrids detected
after treatment with RNAse, which cleaves the
heteroduplex where there is a mismatch [22].
PCR–DNA sequencing
PCR–DNA sequencing is the most direct way of
defining resistance genotypically and is the stan-
dard of molecular assignment of resistance. It
requires no more than the amplification of a region
which includes the codons involved in the resis-
tance, and these amplicons are sequenced to assign
to the presence/absence of a specific mutation. Its
limitation is that it is expensive and requires
expertise. Although automatic sequencers are
increasingly available in health-care institutions,
they are not readily available in all microbiology
laboratories. Nevertheless, DNA sequencing is the
technique of choice according to several studies on
the genotypic detection of resistant TB strains. It
has been applied to isolates from a wide variety of
geographic origins, in the search for mutations in
multiple loci of: MDR strains [23], RIF-r in rpoB
[8,9,24–26], RIF-r outside the RRDR core [27], INH
in ndh [28], and katG [29], and EMB-r [17,30,31].
Hybridization-based techniques
Hybridization-based techniques comprise a hetero-
geneous group. Some of them are performed on
PCR assays which include specific DNA probes,
and others are conventional hybridization assays
in solid or liquid formats. All of them are based on
the hybridization of two strands of DNA, one from
the clinical strain and another from the consensus
probe/oligonucleotide. The hybridization of the
two strands is highly stable when it involves fully
complementary sequences; if a mismatch occurs
in some nucleotidic position, owing to genetic
differences between the clinical strain and the
consensus sequence, the binding of the two
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strands is thermodynamically impaired. In order
to appreciate more clearly the peculiarities of these
techniques, all PCR-based assays using hybridiza-
tion probes have been grouped under the heading
‘Real-time PCR’, and in this section only the immo-
bilized hybridization formats are reviewed.
Hybridization on strips
One adapted hybridization design for the detec-
tion of resistance to rifampicin involves the use of
commercial membrane strips in which a set of ten
oligonucleotide probes is immobilized (INNO-
LipA; Innogenetics, Gent Belgium). Five of these
probes are homologous with five subregions
which together constitute the rpoB core region,
four other probes are designed to be homologous
with frequent Rif-R mutations, and another probe
is an amplification control for the MTB complex.
The method follows a reverse-hybridization
design in which the labeled probe is constituted
by the amplicon of the rpoB core region obtained
from the clinical sample by PCR. The label (biotin)
is incorporated in the amplicon during the PCR.
The labeled amplicon is hybridized with the
immobilized probes under stringent conditions.
The hybridized complexes are detected by incuba-
tion with peroxidase-steptavidine and subsequent
addition of a chromogen. If any of the five probes
which are homologous with wild-type sequences
fail to hybridize, a mutation is suspected for the
region covered by that probe. Furthermore, if any
of the probes that are homologous with a mutation
give a positive hybridization signal, it is possible to
specify the mutation responsible for the resistance.
The technique is simple and needs no expertise in
molecular biology, but it does require a pre-PCR
step to amplify and label the clinical amplicon, and
a subsequent hybridization step, which requires a
specific device. Its application to clinical isolates
shows a good correlation with DNA sequencing
(only 2–4% of discrepancies with DNA sequen-
cing/phenotypic assays) [32–34], as well as a good
performance directly on clinical samples [35]. Its
sensitivity increases when using a nested-PCR
approach [36]. With regard to the ability to assign
the specific resistance mutation, a number of cases
have been reported in which certain mutants, fre-
quently insertions, could not be detected [34,37,38].
Hybridization in microplates
A PCR–ELISA format has also been developed for
the detection of RIF-r strains [39]. In this assay, five
independent oligonucleotides, homologous to the
corresponding wild-type sequences, which cover
the core rpoB, were designed as capture probes,
and immobilized to the wells of a microtiter plate.
The rpoB region from the clinical isolate is ampli-
fied and labeled with digoxygenin and hybridized
to the immobilized probes. After developing, posi-
tive signals correspond to amplicons lacking a
mutation in the region covered by the probe and
negative signals indicate the presence of a muta-
tion in that region. This format was tested success-
fully with a collection of clinical strains and also
directly on clinical samples.
Hybridization on arrays
One of the most recent developments in mutation
detection, together with real-time PCR, is the use of
oligonucleotide arrays or biochips. Different stra-
tegies have been followed to adapt these formats to
the analysis of RIF-resistance mutations in MTB.
The assay is based on the hybridization of DNA
from the clinical sample to a set of oligonucleotides,
each one corresponding to a different variant of
rpoB mutation, immobilized either in polyacryla-
mide gel pads (MAGIChip) [40] or in miniaturized
glass substrates (GeneChip, Affymetrix Inc., Santa
Cruz, CA) [41]. The rpoB region from the analysis
strain is amplified and fluorescent-labeled by PCR,
and hybridized to the microarray oligonucleotides.
Fluorescence is higher for the immobilized oligo-
nuleotides that were homologous with the ampli-
con and the presence of a mismatch would
destabilize the duplex leading to a reduction in
fluorescence. The relative fluorescence intensity
between the different positions in the microarray
will define the pattern of mutations in the clinical
strain. This format allows interrogation for the
existence of 30 different rpoB variants in the poly-
acrylamide array [40] in 24 h, and 51 different
variants in the GeneChip version [41] in 4 h.
Real-time PCR
The use of fluorescence labels and the inclusion of
optical devices or CCD cameras in thermocyclers
have recently made it possible to observe an ampli-
fication reaction directly while it is occurring.
The so called ‘real-time PCR’ involves real-time
monitoring of a DNA amplification reaction by
measuring the fluorescence signal accumulated
by amplification products. Different real-time
PCR instruments are available, some based on
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conventional peltier-based thermocyclers and
others on air-heating and air-cooling thermocylers
which, in combination with capillary tubes, also
allow a rapid-cycle PCR.
Different reaction formats have been developed
to monitor a PCR reaction in real time by the use of
fluorescent dyes. If the purpose is to detect specific
mutations in the amplified region, then the fluor-
escent dye must be bound to DNA probes designed
to be complementary to the template DNA under
analysis. Different formats of labeled probes can be
adapted to the detection of mutations. Among the
most frequently used are TaqMan, molecular bea-
cons, and FRET (fluorescence-resonance-energy-
transfer) probes. These probes are included in the
PCR reaction together with the other reagents and
are designed to be homologous with the DNA
region in which a mutation is to be searched for.
TaqMan probes
TaqMan probes are fluorescence-labeled at the 50-
end and include a fluorescence quencher at the 30-
end (Figure 1). The probe anneals to the amplified
target in each of the annealing steps of the PCR.
While it is bound to its homologous sequence, the
real-time PCR instrument does not measure fluor-
escence, because the quencher absorbs the energy
of the dye. In the elongation step of the PCR, the 50-
30exonuclease activity of the Taq polymerase
releases the fluorescent dye which enhances the
emission of fluorescence owing to the separation of
the quencher from the dye (Figure 1). This fluor-
escence is measured by the real-time PCR instru-
ment. Of note is the fact that fluorescence is only
emitted if the probe is correctly anchored to its
homologous site to allow the Taq polymerase to
release the dye. This is the basis for the detection of
mutations using TaqMan probes; if a mismatch
(mutation) impairs the binding of the probe, the
Taq polymerase would not meet the probe and the
fluorescense would remain quenched. Therefore,
the absence of fluorescence indicates the presence
of a mutation in the genetic region covered by the
probe (Figure 1).
One study has used this kind of probe to detect
resistance mutations for RIF and INH in MTB in
cultured strains and clinical samples [42] obtaining
a 100% specificity and a sensitivity of 97% and
40%, for cultured strains or clinical samples,
respectively.
A requirement of real-time PCR assays using
Taq probes is the addition to the PCR reaction of
internal amplification controls, with their respec-
tive complementary probes, to guarantee that the
absence of fluorescence is due to the existence of a
mutation and not to deficiencies in the PCR.
Beacons
Molecular beacons have a stem-loop structure
when in solution (Figure 2). The loop consists of
the sequence which is homologous with the target
DNA. A fluorescent dye and a quencher are in the
Figure 1 Schema of the mechanism
of action of TaqMan probes. In each
of the annealing steps, the probe
binds to its complementary region
in the amplicon. The quencher limits
the fluorescence emission. In the
elongation step, the Taq polymerase
meets the bound probe and its 50-
30exonuclease activity releases the
fluorophore from the probe, which
can then emit fluorescence. If a muta-
tion exists in the region covered by
the probe, it is not efficiently bound
to the template DNA and thus the
fluorophore cannot be released by
the Taq polymerase. The presence
of a mutation is detected by a reduc-
tion in fluorescence measured by the
real-time PCR instrument.
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5 and 30ends of the probe and lie in close proximity
when the probe is in its hairpin conformation. The
stem-loop structure is disrupted when the beacon
binds to its homologous sequence in the target
DNA and the quencher is located far from the dye
which enhances the fluorescence (Figure 2). This
works in the same way as TaqMan probes. If a
mutation maps in the region covered by the probe,
its binding to the target is impaired and the beacon
remains in its stem-loop conformation, without
emitting fluorescence. Internal amplification con-
trols must be added to the PCR to determine
whether the reduction in fluorescence is really
due to mutations, or alternatively, to amplification
inhibitions. Beacons were first adapted for the
detection of RIF-r in MTB [43] by including inde-
pendent probes in different reaction tubes.
Recently, a version of these beacons, called wave-
length-shifting molecular beacons, allows each
probe to be labeled with different dyes which
permit the simultaneous analysis of the whole
rpoB region in a single reaction tube by following
the reaction through independent channels in the
real-time instrument [44].
FRET probes
FRET probes are paired probes which are designed
to anneal to the DNA template in a head-to-tail
orientation with each probe close to the next
(Figure 3). One probe (anchor) is fluorescence-
labeled at its 30end and the adjacent probe (sensor)
is labeled at 50 with a dye which can be excited by
the fluorescence of the anchor. The sensor probe is
designed to overlap with the mutation which is to
be searched for. When the FRET probes are cor-
rectly bound to their homologous target at the end
of the annealing step of the PCR, a process of
energy transfer enables emission of the fluorescein
to excite the dye in the adjacent probe. The fluor-
escence emission from the sensor probe is mea-
sured by the real-time instrument (Figure 3). This
energy transfer only occurs if the distance between
the probes is 1–5 nucleotides, which is only the
case if the two probes are specifically bound to
their homologous target.
In this format, the mutation analysis is different
than that explained for TaqMan or beacon probes,
and this analysis is performed in a melting step at
the end of the PCR. This melting step involves a
slow increase in temperature (0.05–0.2 8C/ s) to
release the sensor probe from its target and thus
monitor the melting of the probes by measuring
the progressive reduction in fluorescence emis-
sion. The analysis software represents the melting
of the probe as a melting peak with a melting
temperature value (Tm). This melting temperature
Figure 2 Schema of the mechanism
of action of molecular beacons show-
ing the stem-loop conformation of a
beacon when in solution, with the
fluorescence sequestered by the
quencher. In each annealing step,
the beacon binds to the template
DNA and acquires a linear conforma-
tion which increases the distance
between the quencher and the dye
thus allowing fluorescence emission.
If a mutation exists in the region cov-
ered by the beacon, binding of the
beacon to DNA is not stable and the
beacon remains in solution without
emitting fluorescence. The presence
of a mutation is detected by a reduc-
tion in fluorescence measured by the
real-time PCR instrument.
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is constant for a pair of probes when bound to the
wt sequence. If a mutation maps in the region
covered by the probe, the mismatch between the
probes and the template leads to a decrease in
the Tm of the probes (Figure 3). Therefore, devia-
tions in the Tm of the probes with respect to the
reference wild-type value correspond to the pre-
sence of a mutation in the region covered by the
probe.
Different studies have adapted FRET probes in
different ways to the analysis of RIF and INH
resistance. One of the approaches searches for
specific mutations in rpoB core, katG [45] and inhA
[46] by using multiple FRET probes specialized in
specific mutations. This involves performing mul-
tiple independent reactions for the whole analysis.
The other approach [47] offers a simplified model
for detecting, in a single reaction tube, all the
mutations related to RIF-r and the most prevalent
for INH-r with only three pairs of FRET probes
and two independent measurement channels.
This is achieved by a design of FRET probes with
both paired probes acting as mutation sensors,
different from the conventional anchor-sensor
design. This design succeeded in detecting 14
different mutations affecting nine codons in the
same reaction. This could serve as a reference for
adapting real-time PCR to the detection of multi-
ple mutations using simple and less expensive
designs which are suitable for different geographic
settings.
Unlike TaqMan or beacons, FRET probes do not
require amplification controls in the reaction,
because the detection of mutations is not based
Figure 3 Schema of the mechanism of action of FRET probes. Upper part: in the annealing step the two FRET probes (anchor
and sensor) bind to the template DNA. The head-to-tail positioning of the probes allows the two dyes to be close to each
other. By a process of energy transfer, excitation of the anchor dye stimulates the sensor dye, which in turn emits
fluorescence. Lower part: the behavior of the sensor probe in the post-PCR melting step is shown for a wild-type and
mutant sequence. The sensor probe is melted at lower temperature when a mutated sequence is found owing to a
thermodynamically impaired binding of this probe. The presence of a mutation is detected by a deviation in the melting
temperature of the probe.
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on the presence or absence of a fluorescent signal
but rather, on deviations in the Tm values of a
positive amplification signal.
Biprobes
Biprobes are single probes which are fluorescently
labeled at the 50end. In real-time PCR, biprobes are
included in the reaction mix together with Sybr-
Green, a dye that emits fluorescence when it binds
to double-strand DNA. Thus, at the end of each
annealing step of the PCR, the SybrGreen excites
the probe fluorophore by energy transfer, emitting
fluorescence which can be measured by the real-
time PCR instrument. The analysis of mutations
involves monitoring of melting as was explained
for FRET probes. Deviations in the Tm of the
biprobe indicate the presence of mutations. In
one report, this kind of probe correctly assigned
all mutations in 46 rif-R strains by using three
independent biprobes which involve the perfor-
mance of three independent reactions [48].
Other PCR-based techniques
Multiplex allele-specific PCR
Some authors have developed PCR assays designed
to allow the direct discrimination of certain nucleo-
tidic substitutions at specific codons (Figure 4).
These designs are multiplex-PCRs which include
outer primers in the reaction to generate the ampli-
con for analysis, and inner primers (of opposite
reading directions), which are designed to alterna-
tively bind one or the other, depending on the
substitution found at a certain codon. The codon
in the analysis is placed asymmetrically in the
amplicon, causing the length of the PCR fragments
to vary, according to the direction of the inner
primer which binds to the codon in analysis.
Multiplex allele-specific PCRs have been success-
fully assayed to assign resistance to EMB associated
with embB codon 306 [49] and to INH in codon 315
[50] and have shown the ability of these designs to
work directly on the clinical sample.
Multiplex allele-specific PCR has also been
adpated to be performed on biochips. In this ver-
sion [40,51], a set of primers which are homologous
for different rpoB variants is immobilized in the
array (MAGIChip) and all the reagents required for
the PCR are added onto the chip. Amplification
(fluorescence-labeled) only occurs in those posi-
tions in which the primer is complementary to the
clinical amplicon. The fluorescence intensity of
matched or mismatched primers provides infor-
mation on the genetic content of the amplified
DNA from the clinical sample.
F I N A L C O N S I D E R A T I O N S
Several molecular designs to search for mutations
encoding the resistance to antituberculous drugs
Figure 4 Schema of an multiplex allele-specific polymerase chain reaction (PCR). Outer primers (O1 and O2) and inner
primers (I1 and I2), which are all added to the PCR-reagent mix, are indicated. Outer primers always bind to the template
generating a long amplicon. Inner primers are designed so that their 30ends are complementary to different nucleotides in the
codon under analysis. Depending on the sequence in the codon, I1 or I2 would alternatively bind to the DNA leading to
amplicons of different lengths. Depending on the amplicons obtained, the nucleotidic sequences in the codon analyzed can
be specified.
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in MTB have been developed in the last few years.
Most of these are highly efficient for RIF-R detec-
tion and are well adapted to search for the most
relevant INH-R mutations. Nevertheless, addi-
tional efforts should be made to increase the mole-
cular approaches that could efficiently analyze
drug resistances.
These new methods are sure to transform the
standard approaches to the issue of resistance in
the microbiology laboratory. Speed is a key ques-
tion in the detection of resistant MTB strains and,
in this sense, molecular assays are clearly unri-
valled. Their main disadvantages, the need for
expertise and their high costs, are becoming less
important; the role of molecular biologists is pro-
gressively more important in clinical microbiol-
ogy laboratories and the cost of some ‘in-house’
molecular designs could be equivalent to, or even
less expensive than, the costs of phenotypic anti-
biograms if the new liquid-culture media are
used. However, cost, speed or professional exper-
tise are not the only factors to consider. The
molecular analysis of resistance enables us to
obtain additional information and essential data
that are not available if only phenotypic antibio-
grams are obtained. Genotypic analysis not only
detects the resistant strains, but in many cases it
also specifies the mutation involved in the resis-
tance, which helps to identify strains with high
levels of resistance or a broad spectrum of resis-
tance. In addition, the assignment of specific
mutations could be an epidemiological marker
for resistant strains [8]. Furthermore, these mole-
cular methods can detect hetero-resistance by
discriminating different subpopulations in the
clinical sample and therefore help to detect the
emergence of resistance and to follow its devel-
opement in certain cases [52]. Genotyping of
resistance makes it possible to know which muta-
tions do not diminish the fitness of the strain and
thus do not affect the virulence or the ability of the
strain to spread [12].
In conclusion, molecular approaches speed up
the performance of resistance assays and provide
access to essential information for a highly refined
detection, follow-up and management of antibiotic
resistance in TB.
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